Danaher beat Q4 sales and earnings estimates, showed strength in bioprocessing and diagnostics, and issued a steady 2026 outlook, even as shares traded lower in premarket action.
Danaher beat Q4 sales and earnings estimates, showed strength in bioprocessing and diagnostics, and issued a steady 2026 outlook, even as shares traded lower in premarket action.